Anteris Technologies Global Corp美股招股说明书(2026-04-30版)

Prospectus Supplement No. 2(To Prospectus dated March 13, 2026) This prospectus supplement updates, amends and supplements the prospectus, dated March 13, 2026 (the “Prospectus”), which formspart of our Registration Statement on Form S-1 (Registration No. 333-291821) relating to up to 9,103,796 shares of our commonstock, par value $0.0001 per share (“Common Stock”), which may be offered for sale by the selling stockholders identified under theheading “Selling Stockholders” in the Prospectus. This prospectus supplement is being filed to update, amend and supplement theinformation contained in the Prospectus with information contained in our Current Report on Form 8-K, which was filed with theSecurities and Exchange Commission on April 29, 2026 (the “Current Report”).Accordingly, we have attached the Current Report tothis prospectus supplement. This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction withthe Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent thatthe information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep thisprospectus supplement with your Prospectus for future reference. Investing in our securities involves a high degree of risk. See the section titled “Risk Factors” in the Prospectus and in thedocuments incorporated by reference in the Prospectus. Neither the SEC nor any state securities commission has approved or disapproved of the securities to be offered pursuant tothe Prospectus or this prospectus supplement or determined if the Prospectus or this prospectus supplement is truthful orcomplete. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is April 30, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2026 Anteris Technologies Global Corp.(Exact name of registrant as specified in its charter) Delaware(State or Other Jurisdiction ofIncorporation) Registrant’s telephone number, including area code: +61 7 3152 3200 Not Applicable(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrantunder any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Item 1.02 Termination of a Material Definitive Agreement. On April 28, 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the“Company”), notified v2vmedtech, inc. (“v2v”) of its election to discontinue additional development contributions under theContribution and Stock Purchase Agreement dated April 18, 2023 (the “Agreement”). The Company’s election occurred following completion of Stage 1 and during Stage 2 of the development program contemplated bythe Agreement. Pursuant to the Agreement as a result of providing the notice referenced above: •The Company is required to pay a break fee of $400,000 to v2v, which will be used by v2v for continued development of thetechnology.•The Company has no further obligation to make additional development contributions under the Agreement.•The initial shareholders of v2v have the right, at their election, to either:oacquire all of the Company’s equity interest in v2v for an amount equal to the Company’s aggregate contributions todate, ororeduce the Company’s equity interest in v2v to a capped minority ownership percentage as specified in the Agreement. v2v has not informed the Company as to which option it intends to pursue. In addition, as a result of the termination of the Company’s obligation to make further development contributions to v2v under theAgreement, the Development Agreement by and between the Company, dated as April 18, 2023 (the “De